Peginterferon alfa-2a
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (8) | US (FDA) | PEGASYS | — | 2002-12-03 – 2023-12-11 | fda.gov ↗ |
| Approved | US (FDA) | PEGASYS | — | 2002-10-16 | fda.gov ↗ |
| Approved | EU (EMA) | Pegasys | — | 2002-06-20 | europa.eu ↗ |
Trials 227 · started per year
News releases announcing trial results or a regulatory action · 94
| Date | Issuer | Release |
|---|---|---|
| 2026-07-03 | Brii Biosciences Limited | Results Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B briibio.com ↗
End-of-treatment data from ENHANCE did not demonstrate improved HBsAg loss rates compared to ENSURE Cohorts 2 and 3, informing selection of combination regimen going forward |
| 2026-05-27 | Brii Biosciences Limited | Results Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV briibio.com ↗
Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa ( PEG-IFNα ) alone |
| 2026-04-26 | Brii Biosciences Limited | Results Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026 briibio.com ↗
Participants achieving HBsAg loss with pegylated interferon alfa ( PEG -IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated with clinically significant ALT elevation. |
| 2025-11-10 | Brii Biosciences Limited | Results Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179’s Potential as a Curative Treatment for Chronic Hepatitis B briibio.com ↗
Cohort 4 follow-up confirms durable h epatitis B surface antigen ( HBsAg ) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs respon ders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) |
| 2025-11-07 | Brii Biosciences Limited | Results Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine briibio.com ↗ |
| 2024-11-15 | Vir Biotechnology, Inc. | Results Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting vir.bio ↗
The study demonstrated promising rates of hepatitis B surface antigen (HBsAg) loss (seroclearance) in participants with low baseline HBsAg (<1000 IU/mL) in both combination regimens. |
| 2024-06-07 | Brii Biosciences Limited | Results Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024 briibio.com ↗
BRII-179 as add-on therapy induces functional antibody responses and contributes to improved sustained HBsAg loss in PEG-IFN a -treated participants with chronic HBV infection |
| 2024-06-06 | Gilead Sciences | Results Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA gilead.com ↗
Data Published in NEJM Demonstrate 46% of Patients Taking Bulevirtide 10 mg with PegIFN Achieved Post-Treatment Undetectable HDV RNA at Week 24 |
| 2024-05-22 | Gilead Sciences | Results Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024 gilead.com ↗
Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver |
| 2023-11-13 | Vir Biotechnology, Inc. | Results Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023 vir.bio ↗
Specifically, at 24 weeks, 15.0% and 14.3% of participants achieved HBsAg loss at EOT for VIR-3434 + VIR-2218 and VIR-2218 + VIR-3434 + PEG-IFN-α, respectively. |
| 2023-09-06 | Brii Biosciences Limited | Results Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B briibio.com ↗
BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFN α increases HBsAg loss rate at the end of treatment and 12 weeks follow up |
| 2023-06-26 | Ascletis Pharmaceuticals Co., Ltd. | Results Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023 ascletis.com ↗
In total, 122, 119, and 107 adverse events (AEs) were reported in 10 mg ASC42, 15 mg ASC42 and PBO cohorts, respectively, and most AEs (94.3%) were mild (grade 1) or moderate (grade 2) in severity. |
| 2023-06-25 | Brii Biosciences Limited | Results Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023 briibio.com ↗
16% (5/31) of participants demonstrated sustained HBsAg loss 24 weeks after end of treatment; Two of the five participants had baseline HBsAg levels greater than 1,000 IU/mL. |
| 2023-06-21 | Assembly Biosciences | Results Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023 assemblybio.com ↗
The first-generation core inhibitor candidate, VBR, was evaluated in a Phase 2 study in combination with entecavir (ETV) and pegylated interferon alpha (Peg-IFNα) in patients with hepatitis B e antigen positive cHBV infection. |
| 2021-06-24 | Gilead Sciences | Results Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks gilead.com ↗
Results from the Phase 2b trial show that treatment with bulevirtide alone or in combination with peginterferon alfa-2a, is associated with a significant HDV RNA decline and improvements in biochemical disease activity at Week 24. |
| 2020-03-09 | Replicor Inc. | Results Replicor announces publication of the REP 401 study achieving high rates of virologic control and functional cure in patients with chronic hepatitis B infection replicor.com ↗
Importantly 78% of participants achieved virologic control of HBV of whom 39% further achieved functional cure. |
| 2019-02-11 | Replicor Inc. | Results Replicor to update analysis of high rates of functional cure of HBV at APASL 2019 replicor.com ↗
demonstrating further treatment is no longer required in 85% of patients completing therapy |
| 2018-11-06 | Replicor Inc. | Results Replicor to disclose achievement of high rates of functional cure of HBV at AASLD 2018 replicor.com ↗
Replicor’s poster presentation (Poster 393), to be presented on Friday, November 9, 2018, will showcase the on-going follow-up analysis after removal of all treatment (now beyond 24 weeks in most patients) indicating normalization of liver function |
| 2018-06-18 | Replicor Inc. | Results Replicor demonstrates high rates of persistent functional control of HBV infection following cessation of all therapy replicor.com ↗
Liver function is normal in 92% of these patients. |
| 2017-10-23 | Replicor Inc. | Results Replicor discloses the persistence of functional control off-therapy in 80% of patients with chronic hepatitis B from the REP 401 study at AASLD 2017 replicor.com ↗
This functional control is persisting in all patients (80%) after removal of all therapy with data available for 24 weeks in 4 patients, 12 weeks in 3 patients and 4 weeks in 1 patient. |
| 2017-10-10 | Replicor Inc. | Results Replicor to disclose late-breaking follow-up data from its REP 401 study at AASLD 2017 replicor.com ↗
control of HBV infection (HBsAg, anti-HBs and HBV DNA) and normalization of liver function is currently persisting for up to 24 weeks after withdrawal of all therapy |
| 2017-09-28 | Replicor Inc. | Results Replicor announces publication of its REP 301 study in HBV / HDV co-infection in The Lancet Gastroenterology & Hepatology replicor.com ↗
The critical importance of HBsAg reduction below 1IU/mL was emphasized by the lack of potentiation of pegIFN in three patients who achieved HBsAg levels as low as 16.4, 5.74 and 1.88 IU/mL during exposure to pegIFN. |
| 2017-04-21 | Gilead Sciences | Results Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection gilead.com ↗
The studies demonstrated HCV cure rates of 99 percent in children aged 6 to 11 years (#PS-101), and 100 percent in adult patients co-infected with HCV and hepatitis B virus (HBV) (#PS-098). |
| 2017-04-21 | AbbVie | Results Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C abbvie.com ↗
In results from the Phase 3 ENDURANCE-3 study, 95 percent (n=149/157) of GT3 chronic HCV infected patients without cirrhosis and who are new to treatment achieved sustained virologic response at 12 weeks post-treatment (SVR 12 ) following 8 weeks of treatment with G/P. |
| 2017-02-20 | Replicor Inc. | Results Replicor discloses high rates of HBsAg loss with NAP combination therapy at APASL 2017 replicor.com ↗
In patients receiving NAPs in combination with TDF and peg-IFN, 8/9 patients receiving REP 2139 have experienced HBsAg reductions > 4 logs with HBsAg loss (HBsAg ≤ 0.01 IU / ml) in 7 of these patients. |
| 2016-11-15 | Replicor Inc. | Results Replicor discloses late breaking HBV and follow-up HBV / HDV clinical data at AASLD 2016 replicor.com ↗
After 24 weeks of follow-up, despite the use of a suboptimal combination regimen, 5/12 patients had no detectable HBsAg and 7/12 patients had no detectable HDV RNA, indicating that functional control of infection has been established in these patients. |
| 2016-06-07 | Replicor Inc. | Results Replicor announces publication of its REP 101 and REP 102 studies demonstrating the therapeutic effect of NAPs and the achievement of functional control off treatment in human patients with chronic hepatitis B infection. replicor.com ↗
In both studies, NAP monotherapy was accompanied by 2 – 7 log reductions of serum HBsAg, 3 – 9 log reductions in serum HBV DNA, seroconversion of HBeAg and the appearance of serum anti-HBsAg antibodies. |
| 2015-12-01 | Replicor Inc. | Results Replicor to present pre-clinical and clinical data on REP 2139-Ca based combination therapy in chronic HBV / HDV co-infection at HEPDART 2015 replicor.com ↗
HDV RNA is now currently undetectable in ten patients (~5-8 log reduction from baseline). |
| 2015-11-16 | Replicor Inc. | Results Replicor discloses continued improvement of the antiviral response in patients with HBV / HDV co-infection receiving REP 2139-Ca based combination therapy replicor.com ↗
HDV RNA continued to decline in all patients and is now currently undetectable in ten patients (~5-8 log reduction from baseline). |
| 2015-06-30 | Replicor Inc. | Results Replicor discloses updated clinical trial data to the Global Virus Hepatitis Summit in Berlin replicor.com ↗
These data demonstrate the continued elimination of serum HDV RNA during combination treatment in all patients. |
| 2015-06-10 | Replicor Inc. | Results Replicor to Present at the Israel Association for the Study of Liver Conference and the Global Virus Hepatitis Summit in Berlin in June replicor.com ↗
The data from the previous three clinical trials, together with the preliminary data from the REP 301 trial, demonstrate that REP 2139 used alone or in combination with Pegasys® or ZADAXIN® or Pegasys® and ETV is safe and well-tolerated. |
| 2015-04-13 | Ascletis Pharmaceuticals Co., Ltd. | Results HCV RACE IN CHINA ascletis.com ↗
In 30 non-cirrhotic patients with genotype 1b infection, 97% achieved an SVR12. |
| 2015-04-10 | Replicor Inc. | Results Replicor to Present at the 2015 Lancet Viral Hepatitis Conference replicor.com ↗
These clinical trials indicated that REP 2139-Ca appears to significantly increase the 12-month SVR rate achieved compared to existing therapies. |
| 2015-03-23 | Ascletis Pharmaceuticals Co., Ltd. | Results Ascletis’ triple therapy HCV drug nails phase II trial in Chinese patients ascletis.com ↗
The study results indicate that ASC08, in combination with peginterferon alfa 2a plus ribavirin, can deliver better cure rate in Chinese patients where genotype 1b predominates, as compared to Caucasian patients where genotype 1a predominates, |
| 2014-12-01 | Replicor Inc. | Results Replicor a biopharmaceutical company targeting a cure for Chronic Hepatitis B patients will present updated human clinical trial data documenting a 4 to 6 log reduction in s-antigen and a long-term SVR in 80% of patients. replicor.com ↗ |
| 2014-10-07 | Replicor Inc. | Results Replicor to present updated clinical trial data with combination treatment using its HBsAg-release inhibitors in patients with chronic hepatitis B infection at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society. replicor.com ↗
when used with a full course of Pegasys™, NAP therapy has resulted in the establishment of long term SVR in 80% of patients. |
| 2014-06-15 | Gilead Sciences | Results Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan gilead.com ↗
Among patients receiving 12 weeks of LDV/SOF without RBV, 100 percent (n=83/83) of treatment-naïve and 100 percent (n=88/88) of treatment-experienced patients achieved a sustained virologic response 12 weeks after completing therapy (SVR12). |
| 2014-04-12 | Janssen Research & Development, LLC | Results Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) jnj.com ↗
In patients with the IL28B CT and TT genotypes, 66 percent and 60 percent achieved SVR12, respectively. |
| 2014-04-10 | Gilead Sciences | Results Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy gilead.com ↗
Among the 50 patients for whom sustained virologic response data was available 12 weeks after the end of treatment (SVR12), 74 percent (n=37/50) achieved SVR12. |
| 2013-10-18 | Medivir | Results Medivir announces data from two phase III studies with Simeprevir in hepatitis C subpopulations – HCV/HIV co-infected and genotype 4 infected patients medivir.com ↗
Medivir AB (OMX: MVIR) today announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients. |
| 2013-05-21 | Janssen Research & Development, LLC | Results Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients jnj.com ↗
In the simeprevir arm, on-treatment failure rates were 3 percent and relapse rates were 19 percent, compared to 27 percent and 48 percent in the placebo arm. |
| 2013-05-14 | Replicor Inc. | Results Replicor presents clinical efficacy and toxicology results in patients with chronic hepatitis B with short term exposure to immunotherapy after REP 2139-ca induced clearance of serum HBsAg. replicor.com ↗
the addition of immunotherapy (either Pegasys™ or Zadaxin™) after REP 2139-ca mediated HBsAg clearance led to profound increases in immune function in all patients |
| 2013-04-26 | Replicor Inc. | Results Replicor presents updated clinical efficacy results in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139-ca and new clinical data in patients receiving this combination treatment while currently on entecavir (triple combination therapy). replicor.com ↗
Profound increases in anti-HBV antibodies or immune function were observed in all patients with as few as 6-10 weeks of combination treatment. |
| 2013-04-23 | Boehringer Ingelheim | Results Boehringer Ingelheim's Faldaprevir-Based Treatment Regimen Achieved Viral Cure in up to 80 per cent of Patients with Hepatitis C in Phase 3 Pivotal Trial(1) prnewswire.com ↗
In previously untreated patients with genotype-1 hepatitis C virus (HCV) who received once-daily faldaprevir plus PegIFN/RBV, 79% and 80% in the 120mg and 240mg arms, respectively, achieved viral cure when measured 12 weeks after treatment was completed (SVR12). |
| 2013-04-23 | Janssen Research & Development, LLC | Results Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients jnj.com ↗
In both studies, 50 percent of patients receiving pegylated interferon and ribavirin alone achieved SVR12. |
| 2013-03-26 | Gilead Sciences | Results Gilead Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients gilead.com ↗
This recommendation is based upon the observed SVR4 rates exceeding the predefined threshold of 60 percent and the absence of significant safety issues. |
| 2013-02-27 | Replicor Inc. | Results Replicor updates clinical efficacy results in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139 replicor.com ↗
Profound increases in anti-HBV antibodies or immune function were observed in all patients with as few as 6-10 weeks of combination treatment. |
| 2013-02-04 | Gilead Sciences | Results Gilead Announces Sustained Virologic Response Rates from Two Phase 3 Studies of Sofosbuvir for Hepatitis C gilead.com ↗
All common adverse events (≥10 percent in any group) occurred more frequently in subjects receiving peg-IFN and RBV as compared to sofosbuvir and RBV. |
| 2012-11-12 | Replicor Inc. | Results Replicor updates clinical results demonstrating the achievement of therapeutic vaccine-like responses in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139 replicor.com ↗
All patients have achieved HBV antibody levels seen in healthy patients after vaccination with a total of 12 weeks of combination treatment and many patients have achieved antibody titers > 1000 mIU / ml. |
| 2012-11-11 | Scynexis, Inc. | Results SCYNEXIS’ Oral SCY-635 Shows Potential as an Immune Acting Antiviral to Augment Current HCV Treatments scynexis.com ↗
The Phase 2a study found that SCY-635 administered for only four weeks restored sensitivity to Peg-IFN/RBV therapy in a difficult to treat, HCV genotype 1 infected population. |
| 2012-11-10 | Boehringer Ingelheim | Results Phase 2b Data of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients prnewswire.com ↗
Addition of the NS5B polymerase inhibitor BI 207127 to pegylated interferon and ribavirin (PegIFN/RBV) for 4 weeks followed by PegIFN/RBV for 44 weeks improves SVR24 rates in treatment-naive patients with HCV genotype (GT) 1 and is well tolerated |
| 2012-11-10 | Vertex Pharmaceuticals Incorporated | Results Vertex Presents New Phase 3 Data that Showed People with Hepatitis C Treated with Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily vrtx.com ↗ |
| 2012-11-01 | Vertex Pharmaceuticals Incorporated | Results Vertex Reports Third Quarter 2012 Financial Results and Recent Progress in Development Programs vrtx.com ↗
Adverse events were generally similar between both arms of the study and consistent with previous studies. |
| 2012-10-16 | Bristol-Myers Squibb | Results Bristol-Myers Squibb to Present New Data Demonstrating Company’s Continuing Commitment to Research and Development in Liver Disease at The American Association for the Study of Liver Diseases (AASLD) Annual Meeting bms.com ↗
Peginterferon Lambda-1a (Lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to Peginterferon alfa-2a (Alfa) |
| 2012-09-25 | Replicor Inc. | Results Replicor discloses achievement of therapeutic vaccine-like responses in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139 replicor.com ↗
Profound increases in anti-HBV antibodies or immune function were observed in all patients with as few as 6-10 weeks of combination treatment. |
| 2012-04-19 | Bristol-Myers Squibb | Results Investigational Compound Peginterferon Lambda Achieved SVR24 Rates Comparable to Peginterferon Alfa with Fewer Flu-Like and Musculoskeletal Symptoms in Phase IIb Study in Treatment-Naïve Genotype 2 or 3 Hepatitis C Patients bms.com ↗
In this study, the investigational compound peginterferon lambda-1a (Lambda) plus ribavirin (RBV) achieved sustained virologic response rates 24 weeks post-treatment (SVR 24 ) that were comparable to peginterferon alfa-2a (alfa) plus ribavirin. |
| 2012-03-06 | Vertex Pharmaceuticals Incorporated | Results Data from Phase 2 Study of an INCIVEK® Combination Regimen Showed 74% of People Co-Infected with Hepatitis C and HIV Had Undetectable Hepatitis C Virus 12 Weeks After Treatment Ended (SVR12) vrtx.com ↗ |
| 2011-11-08 | Boehringer Ingelheim | Results Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types prnewswire.com ↗
Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from two Phase 2 studies evaluating the combination of the company's protease inhibitor, BI 201335, with pegylated interferon (PegIFN) and ribavirin (RBV) in treatment-naive genotype-1 (GT1) hepatitis C virus (HCV) patients. |
| 2011-11-05 | Vertex Pharmaceuticals Incorporated | Results Positive Interim Data From a Phase 2 Study of INCIVEK™ (telaprevir) Combination Therapy in People Co-Infected with Hepatitis C and HIV Presented at The Liver Meeting® vrtx.com ↗
Data showed 74 percent (28/38) of patients who were treated with INCIVEK (in-SEE-veck) combination therapy had undetectable hepatitis C virus (HCV RNA) at Week 24 of treatment compared to 55 percent (12/22) who were treated with pegylated-interferon and ribavirin alone. |
| 2011-11-05 | Vertex Pharmaceuticals Incorporated | Results Interim Data from Phase 2 Study Showed 93% of People with Hepatitis C Who Received a Total of 12 Weeks of a Combination Regimen Including INCIVEK™ (telaprevir) and VX-222 (400mg) Achieved a Viral Cure (SVR) vrtx.com ↗
Fifty percent (15/30) of patients who received the combination regimen including VX-222 (400mg) were eligible for a total of 12 weeks of treatment and 93 percent (14/15) of them achieved a viral cure (sustained viral response, or SVR). |
| 2011-09-17 | Bristol-Myers Squibb | Results BMS-790052 Plus Peginterferon Alfa and Ribavirin Demonstrated up to 83% Sustained Virologic Response 24 Weeks Post-Treatment (SVR24) in Phase II Study of Genotype 1 Hepatitis C Patients bms.com ↗
In this Phase II study, adding BMS-790052 once daily to peginterferon alfa and ribavirin produced SVR rates and safety findings that warranted further development of BMS-790052. |
| 2011-09-14 | Vertex Pharmaceuticals Incorporated | Results New England Journal of Medicine Publishes Data from Phase 3 ILLUMINATE Study of INCIVEK™ (telaprevir) in Hepatitis C vrtx.com ↗
In this study, 65 percent (352/540) of people had undetectable hepatitis C virus at weeks 4 and 12. |
| 2011-07-26 | Vertex Pharmaceuticals Incorporated | Results Interim Data from Phase 2 Study of Combination Regimen Including VX-222 and INCIVEK™ Suggest Potential to Treat Genotype 1 Hepatitis C in as few as 12 Weeks and No More Than 24 Weeks vrtx.com ↗
The hepatitis C virus was undetectable in 100 percent (13/13) of these patients at the end of 24 weeks. |
| 2011-04-04 | Enanta Pharmaceuticals, Inc | Results Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C enanta.com ↗
At week 12, 92 percent of patients receiving ABT-450/r (ABT-450 with 100 mg of ritonavir to support once-daily dosing) in combination with standard of care (SOC) – pegylated interferon alpha and ribavirin (pegIFN/RBV) – achieved HCV-RNA <25 IU/mL |
| 2011-04-01 | Boehringer Ingelheim | Results Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients prnewswire.com ↗
Results from SILEN-C1 show a sustained viral response (SVR) in 71 to 83 percent of treatment-naive patients who received BI 201335 once-daily plus the current standard-of-care (SOC) [pegylated interferon (PegIFN) and ribavirin (RBV)]. |
| 2011-03-31 | Vertex Pharmaceuticals Incorporated | Results Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantly Improved SVR (Viral Cure) Rates in People Whose Prior Treatment For Hepatitis C Was Unsuccessful vrtx.com ↗
Data from the study showed that people in each of these subgroups who were treated with telaprevir-based combination therapy achieved superior rates of sustained viral response (SVR, or viral cure) compared to those treated with pegylated-interferon and ribavirin alone. |
| 2011-03-31 | Vertex Pharmaceuticals Incorporated | Results Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C vrtx.com ↗
Among those who received VX-222 (400 mg) in combination with telaprevir, pegylated-interferon and ribavirin, interim data showed that 90 percent (27/30) of them had undetectable hepatitis C virus at week 12. |
| 2011-03-31 | Vertex Pharmaceuticals Incorporated | Results Data From Phase 3 Studies Showed Substantial Improvements in SVR (Viral Cure) Rates With Telaprevir-Based Therapy Compared to Currently Available Medicines in People With Hepatitis C, Regardless of Their IL28B Genotype Status vrtx.com ↗ |
| 2011-03-07 | Bristol-Myers Squibb | Results New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver Congress 2011 bms.com ↗
Pegylated Interferon-Lambda (PEGIFN-λ) shows superior viral response with improved safety and tolerability versus PEGIFNα-2A in HCV patients (G1/2/3/4): EMERGE Phase IIb through week 12 |
| 2011-03-02 | Vertex Pharmaceuticals Incorporated | Results Positive Phase 2 Interim Data from First Study of Telaprevir in People Co-Infected with Hepatitis C and HIV Presented at CROI Conference vrtx.com ↗
HIV viral load and CD4 counts were stable among patients receiving a telaprevir-based regimen. |
| 2010-10-30 | Gilead Sciences | Results Gilead's Investigational Hepatitis C Compounds GS 9190 and GS 9256 in Combination with Standard of Care Therapies Achieve Substantial Viral Suppression in Phase II Study gilead.com ↗
Gilead Sciences, Inc. (Nasdaq:GILD) today announced data from a Phase IIa study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus (HCV) within 28 days of treatment. |
| 2010-10-30 | Vertex Pharmaceuticals Incorporated | Results New Data From Phase 3 Studies Showed Superior SVR (Viral Cure) Rates Achieved with Telaprevir-Based Combination Therapy in People with Hepatitis C, Regardless of Race or Stage of Liver Disease vrtx.com ↗ |
| 2010-09-07 | Vertex Pharmaceuticals Incorporated | Results 65% of People Whose Prior Treatment for Hepatitis C Was Unsuccessful Achieved SVR (Viral Cure) with Telaprevir-Based Therapy in Phase 3 REALIZE Study vrtx.com ↗ |
| 2010-05-25 | Vertex Pharmaceuticals Incorporated | Results 75% of Treatment-Naïve Patients with Chronic Hepatitis C Achieve SVR (Viral Cure) with Telaprevir-Based Treatment in Phase 3 Trial vrtx.com ↗
Patients received 750 mg of telaprevir (or placebo) orally (tablets) every eight hours (q8h), a 180 ug injection of peginterferon alfa-2a (Pegasys) once-weekly, and a 1,000 mg or 1,200 mg weight-based daily oral dose of ribavirin (Copegus). |
| 2010-04-07 | Vertex Pharmaceuticals Incorporated | Results New England Journal of Medicine Publishes PROVE 3 Trial Showing Telaprevir-Based Regimens Significantly Increased Sustained Viral Response (SVR) Rates in Patients Who Did Not Achieve SVR with Prior HCV Therapy vrtx.com ↗
In the trial, 51 percent and 53 percent of patients who received telaprevir in combination with pegylated-interferon and ribavirin as part of a 24-week or 48-week regimen, respectively, achieved SVR. |
| 2009-10-31 | Vertex Pharmaceuticals Incorporated | Results More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens vrtx.com ↗
For the majority of patients, these SVR rates were obtained with a 24-week telaprevir-based regimen. |
| 2009-09-24 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting vrtx.com ↗
Telaprevir, Peginterferon Alfa-2a and Ribavirin Improved Rates of Sustained Virologic Response (SVR) in "Difficult-to-Cure" Patients With Chronic Hepatitis C (CHC): a Pooled Analysis From the PROVE 1 and PROVE 2 Trials |
| 2009-04-29 | Vertex Pharmaceuticals Incorporated | Results New England Journal of Medicine Publishes Landmark Clinical Studies of the Investigational Hepatitis C Virus Protease Inhibitor Telaprevir vrtx.com ↗
telaprevir dosed in combination with pegylated-interferon (peg-IFN) and ribavirin (RBV) as part of a 24-week treatment regimen resulted in a significant improvement in the rate of sustained viral response (SVR) |
| 2009-04-28 | Debiopharm International SA | Results Clinical Update – Debio025 in Hepatitis C – Debiopharm presents promising phase IIa results showing potent antiviral activity debiopharm.com ↗ |
| 2009-04-21 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals to Present Data at EASL Suggesting Telaprevir's Potential for Use in a Broad Range of HCV Patients and Highlighting the Company's Expanded STAT-C Portfolio vrtx.com ↗
Interim data from two Phase 2 studies (C209 and C210) in treatment-naïve HCV patients show substantial antiviral activity against HCV genotypes 2 and 4 when telaprevir is combined with the standard of care compared with standard of care alone. |
| 2008-11-01 | Vertex Pharmaceuticals Incorporated | Results New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection vrtx.com ↗
In this analysis, 4 patients (10%) in the q8h alfa-2a and 2 patients (5%) in the q8h alfa-2b arms discontinued due to adverse events and 1 patient (3%) and 3 patients (7%), respectively, experienced virologic breakthrough. |
| 2008-09-24 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Announces Correction to Abstract Data Published in October 2008 Supplement to Hepatology vrtx.com ↗
The correctly labeled table, and the corresponding HCV RNA results, are provided below: |
| 2008-04-28 | Debiopharm International SA | Results Clinical Update – Debio025 in Hepatitis C – Presentation of Phase IIa Efficacy Results debiopharm.com ↗
Data indicates that Debio025 shows an important additive anti-HCV effect when co-administered with pegylated Interferon (Peg-IFN) alpha-2a to treatment- naïve HCV patients. |
| 2008-04-24 | Vertex Pharmaceuticals Incorporated | Results Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment vrtx.com ↗
In the interim analysis, patients treated with telaprevir in combination with peg-IFN and RBV demonstrated a high rate of viral response at week 4 (49 of 60 patients achieved HCV RNA 25 IU/mL). |
| 2008-04-23 | Vertex Pharmaceuticals Incorporated | Results Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments vrtx.com ↗ |
| 2007-07-24 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Reports Second Quarter 2007 Financial Results and Provides Development Pipeline Update vrtx.com ↗
Among the patients who completed 24 weeks of therapy and had undetectable HCV RNA (less than 10 IU/mL) at the end of treatment, fewer than 10 percent had relapsed by the end of 12 weeks post-treatment follow-up. |
| 2007-06-12 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Reports 2007 Pipeline Progress vrtx.com ↗
At this time, Vertex is reporting that the preliminary results are consistent with findings reported for PROVE 1. |
| 2006-10-27 | Vertex Pharmaceuticals Incorporated | Results New Data for Investigational Hepatitis C Drug Telaprevir (VX-950) to be Presented at AASLD Meeting vrtx.com ↗
Clinical investigators will also report that some of these patients have stopped therapy, and that a proportion of them continued to have undetectable HCV RNA after stopping therapy. |
| 2006-05-21 | Vertex Pharmaceuticals Incorporated | Results Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients vrtx.com ↗
Researchers reported for the first time today that 11 of these patients (92%) continue to have no detectable virus in their blood at the end of 12 additional weeks of follow-on peg-IFN+RBV dosing. |
| 2006-04-29 | Vertex Pharmaceuticals Incorporated | Results Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients vrtx.com ↗
Researchers reported for the first time today that 8 of 8 patients who received VX-950 and peg-IFN in combination for 14 days have no detectable virus in their blood at the end of 12 additional weeks of peg-IFN+RBV dosing. |
| 2006-02-07 | Vertex Pharmaceuticals Incorporated | Results Vertex Successfully Completes Key Studies with VX-950 to Prepare for Next Steps in Clinical Program vrtx.com ↗
Plasma HCV RNA levels are less than 10 IU/mL in 12 of 12 patients after 28 days of dosing with VX-950/peg-IFN/RBV in Phase II study |
| 2006-02-06 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Reports 2005 Financial Results vrtx.com ↗
In the study, 12 of 12 patients had plasma HCV RNA levels below the limits of detection of a highly sensitive assay (10 IU/mL; Roche TaqMan®) at 28 days of dosing. |
| 2006-01-09 | Vertex Pharmaceuticals Incorporated | Results VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon vrtx.com ↗
The antiviral activity of the combination through 14 days was significantly greater than the activity of VX-950 administered as a single agent, and much greater than peg-IFN alone. |
| 2004-04-16 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches vrtx.com ↗
results for patients enrolled in the extension phase of a pilot Phase IIa study designed to evaluate the safety and tolerability of merimepodib in combination with peg-IFN and ribavirin |
All press releases naming this drug 108 releases
| Date | Issuer | Release |
|---|---|---|
| Show all 108 releases opens the full record — a long page | ||
Evidence & citations 43 cited values
Every value below carries the sentence it was read from. 437 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peg-interferon alfa-2a | “A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group...” NCT00535847 ↗243“A Pilot, Open-Label, Multicentre Study Evaluating the Long-Term Safety and Tolerability of a Low-Dose Peginterferon Alfa-2a Maintenance Monotherapy in Chronic Hepatitis C...” NCT02762383 ↗ “Recently the investigators have shown that HBeAg negative patients with high HBV-DNA load and low baseline HBsAg levels had a significantly higher HBsAg clearance (positive...” NCT00973219 ↗ “The purpose of this study is to see if treatment with PEG-interferon-alfa-2a (PEG-IFN) plus ribavirin is a more effective treatment for hepatitis C virus (HCV) than...” NCT00008463 ↗ “The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of...” NCT00100659 ↗ “Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8...” NCT01368497 ↗ “An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide...” NCT02068365 ↗ “Pegasys (peginterferon alfa-2a) given in combination with Copegus (ribavirin) given for 24 weeks or 48 weeks in treatment naïve patients with chronic hepatitis C (CHC).” NCT00188240 ↗ “patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks” NCT01471535 ↗ “We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients.” PMID 28210927 ↗ Feb 2017 “we gave patients peginterferon alfa-2a 45 μg per week combined with nilotinib 600 mg daily until 24 months after interferon initiation.” PMID 26687426 ↗ Jan 2015 |
| Known as | alfa | “Adult HBeAg+ interferon-naive patients were randomized (1:1) to weekly lambda (180 μg) or peginterferon alfa-2a (alfa) for 48 weeks.” PMID 26739688 ↗ Dec 2015 |
| Known as | interferon alfa 2 a | “interferon alfa 2 a (pegylated form improving tolerance and maybe enhancing is efficacy)” NCT02201459 ↗ |
| Known as | Interféron pégylé alpha -2a | “PEGASYS 180μg (Interféron pégylé alpha -2a)” NCT00391638 ↗ |
| Known as | PEG | “This study is to evaluate the overall efficacy, and safety profile of the triple combination therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin...” NCT01500772 ↗13“This study will assess the safety and efficacy of alisporivir (ALV) and boceprevir (BOC), each in combination with Peginterferon alfa-2a (PEG) and Ribavirin (RBV), in African...” NCT01446250 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.” NCT01054729 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.” NCT01188772 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection” NCT02480686 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT02583685 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01641640 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01384383 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01497366 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01329978 ↗ “Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01808248 ↗ |
| Known as | PEG-2a | “The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of...” NCT00100659 ↗ |
| Known as | peg-IFN | “Recently the investigators have shown that HBeAg negative patients with high HBV-DNA load and low baseline HBsAg levels had a significantly higher HBsAg clearance (positive...” NCT00973219 ↗17“METHODS: A randomized (1:1) trial of tenofovir disoproxil fumarate (TDF) for 192 weeks with or without peginterferon (PegIFN) alfa-2a for the first 24 weeks, followed by...” PMID 36599136 ↗ Dec 2022 “The purpose of this study is to see if treatment with PEG-interferon-alfa-2a (PEG-IFN) plus ribavirin is a more effective treatment for hepatitis C virus (HCV) than...” NCT00008463 ↗ “Currently, combination therapy with peginterferon (Peg-IFN) and ribavirin (RBV) has become the standard of care for chronic hepatitis C (CHC) patients” NCT00977054 ↗ “We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients.” PMID 28210927 ↗ Feb 2017 “Coinfected and monoinfected patients were enrolled in a treatment trial for pegylated-interferon alpha-2a (peg-IFN) + ribavirin.” PMID 17058240 ↗ Nov 2006 “faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic HCV genotype-1 infection.” PMID 27049487 ↗ May 2016 “patients are randomized to receive peginterferon (pegIFN) alfa-2a 180 microg/week plus either weight-based RBV” PMID 20377423 ↗ Apr 2010 “Subjects will be treated for 24 weeks with PEG-IFN (HIV coinfected subjects will received RBV)” NCT00192569 ↗ “nilotinib + pegylated interferon alpha 2a (PEG-IFN).” NCT01294618 ↗ “PEGASYS® (peginterferon alfa-2a, PegIFN)” NCT01937728 ↗ |
| Known as | PEG-IFN alfa | “Peginterferon Alfa-2a (PEG-IFN alfa)” NCT03852433 ↗ |
| Known as | Peg-IFN alfa-2a: Pegasys (Hoffman La-Roche) | “Peg-IFN alfa-2a: Pegasys (Hoffman La-Roche)” NCT00977054 ↗ |
| Known as | Peg-IFN alpha-2a | “comparing the efficacy and safety of telbivudine in combination with PegIFN alpha-2a with telbivudine monotherapy and PegIFN alpha-2a monotherapy.” PMID 25152207 ↗ Aug 20145“Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin” NCT01272310 ↗ “Pegylated Interferon-Alpha-2A (Peg-IFN-Alpha-2A:Pegasys®) on HIV-1 replication” NCT00594880 ↗ “peginterferon alfa (PEG-IFNalpha)-2a 180 microg one time per week (qwk)” PMID 18666223 ↗ Aug 2008 “Peginterferon alpha-2a (PegIFN alpha-2a)” NCT01289782 ↗ “Peginterferon alpha-2a (PegIFN alpha-2a)” NCT01281839 ↗ |
| Known as | Peg-IFN-α | “Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation” NCT03210506 ↗ |
| Known as | PEG-IFN-α2a | “This randomized, prospective, parallel-group clinical trial compared the efficacy and safety of pegylated interferon α-2a (PEG-IFN α-2a) plus ribavirin and PEG-IFN α-2b plus...” PMID 21281434 ↗ Jan 201111“A Multicenter, Single-arm Trial Evaluating the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-IFNα2a/RBV) in Protease...” NCT01500772 ↗ “Telaprevir (TVR) plus peginterferon-α2a (PEG-IFN-α2a) and ribavirin substantially increases treatment efficacy for genotype 1 chronic hepatitis C virus (HCV) infection versus...” PMID 23685940 ↗ Jul 2013 “As there is currently a lack of consensus on the most appropriate dose and duration of peginterferon alfa-2a (PEG-IFNα-2a) therapy in hepatitis B e antigen (HBeAg)-positive patients” PMID 22045673 ↗ Nov 2011 “Children treated with pegylated interferon alpha-2a (Peg-IFN-α2a) ± ribavirin in the Pediatric Study of Hepatitis C (PEDS-C) trial underwent anthropometric measurements” PMID 22383118 ↗ Jul 2012 “Clinical Trial of the Efficacy of the Combination of Pegylated Interferon (PEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C” NCT00158496 ↗ “Clinical Trial of the Efficacy of Pegylated Interferon (PEG-IFNα-2a) Alone in Egyptian Patients With Acute Hepatitis C” NCT00158522 ↗ “Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week” NCT02021643 ↗ “Peg-IFNα-2a 180 μg every week, or albIFN 900 or 1200 μg every 2 weeks administered subcutaneously” PMID 20600013 ↗ Jun 2010 “combined with pegylated interferon-α2a plus ribavirin (pegIFN-α2a/RBV) for 48 weeks” PMID 30858739 ↗ Feb 2019 “weekly pegylated (Peg)-IFN-α2b or Peg-IFN-α2a immunotherapy” PMID 34049356 ↗ Oct 2021 |
| Known as | PEG-IFNa2a | “peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin” NCT00402428 ↗ |
| Known as | PEG-INF | “Peginterferon alpha-2a (PEG-INF) monotherapy: 180 μg subcutaneous injection once a week for 52 weeks.” NCT00412750 ↗ |
| Known as | Peg-interféron alpha-2a (PEGASYS) | “Peg-interféron alpha-2a (PEGASYS)” NCT01289496 ↗ |
| Known as | Pegasys | “Pegylated interferon plus ribavirin is the standard first-line treatment in patients with chronic hepatitis C virus (HCV) mono-infection. Although the optimal anti-HCV regimen...” PMID 15563253 ↗ 2004118“A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group...” NCT00535847 ↗ “A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and...” NCT00983853 ↗ “This study will evaluate the efficacy and safety of capecitabine (Xeloda) in combination with peginterferon alfa-2a (Pegasys) in participants with advanced liver cancer who...” NCT02576964 ↗ “An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide...” NCT02068365 ↗ “Participants randomized to the control group immediately begin treatment with telaprevir + 180ug of peginterferon alfa-2a (Pegasys) per week and either weight based ribavirin.” NCT01890772 ↗ “SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.” NCT00412334 ↗ “Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.” NCT00107653 ↗ “Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day” NCT00495131 ↗ “Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day” NCT00532701 ↗ “Participants received peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once per week for 48 weeks.” NCT00436163 ↗ |
| Known as | Pegasys (PEG-Interferon alpha-2a) | “Pegasys (PEG-Interferon alpha-2a)” NCT00207311 ↗ |
| Known as | Pegasys (PEG-interferon-Alfa-2A) | “Pegasys (PEG-interferon-Alfa-2A)” NCT01769833 ↗ |
| Known as | Pegasys(R) | “with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk)” NCT00892697 ↗ |
| Known as | PegasysTM | “A Phase II Open-Label Pilot Trial of the Antiretroviral Activity, Safety, and Tolerability of Pegylated Interferon Alfa-2A (40KD) [PegasysTM] in HIV-1 Infected Subjects” NCT00078442 ↗ |
| Known as | PegIFN alfa-2a | “Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC)...” PMID 19852040 ↗ Dec 200915“Patients with hepatitis B e antigen (HBeAg)-positive CHB who received any NA for at least 72 weeks and had a low level of HBV DNA (≤100 IU/mL) were randomized (1:1) to receive...” PMID 35867702 ↗ Jul 2022 “The combination therapy using pegylated interferons (IFNs) such as PEG-IFN alfa-2a has been shown to have a superior efficacy than that using conventional IFN in the treatment...” NCT00154869 ↗ “Treatment with pegylated interferon (peg-IFN) alfa-2a (40KD) results in hepatitis B "e" antigen (HBeAg) seroconversion 6 months after treatment in up to 36% of HBeAg-positive...” PMID 25190434 ↗ Sep 2014 “open-label subcutaneous treatment with pegylated interferon-alfa-2a (Peg-IFNalfa-2a) 180 μg/wk, or albIFN 900 or 1200 μg every 2 weeks for 24 weeks” PMID 20600017 ↗ Jul 2010 “The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.” NCT01513941 ↗ “Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment” NCT00078442 ↗ “standard dose Peg-Interferon alfa-2a (PEG-IFN alfa-2a), Ribavirin (RBV) and Amantadine (AMA)” NCT00299923 ↗ “Participants with HCV received pegylated interferon (PEG-IFN) alfa-2a (180μg/week, n=74)” PMID 21145855 ↗ Nov 2010 “phase III study evaluated peginterferon (PegIFN) alfa-2a treatment” PMID 29689122 ↗ Oct 2018 “180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks.” NCT01925820 ↗ |
| Known as | pegIFNα-2a, Pegasys | “pegIFNα-2a, Pegasys®” NCT01428063 ↗1“PegIFNα-2a (Pegasys)” NCT01290679 ↗ |
| Known as | peginterferon | “We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon α-2a (peginterferon) for a finite duration in a randomized trial.” PMID 26453773 ↗ Oct 20151“To test 2 drugs (VIR-2218 and peginterferon) in people with mild or inactive HBV infection” NCT06092333 ↗ |
| Known as | Peginterferon Alfa-2a (40KD) | “Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.” NCT00107653 ↗2“PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin” NCT00475072 ↗ “Efficacy and Safety of Peginterferon Alfa-2a (40KD)” PMID 29689122 ↗ Oct 2018 |
| Known as | peginterferon alpha-2a | “The researchers aim to investigate the ability of peginterferon alpha-2a to achieve surface antigen loss/seroconversion therapy in inactive carriers with persistently normal...” NCT01471535 ↗31“GOALS: To evaluate the predictive value of complete early virological response (cEVR) on sustained virological response (SVR) following retreatment with peginterferon alpha-2a...” PMID 23442834 ↗ Oct 2013 “This study will evaluate the safety and effectiveness of combination therapy with peginterferon alpha-2a and ribavirin for treating hepatitis C virus (HCV) infection in...” NCT00085917 ↗ “Two hundred HCV-1 patients were randomized (1:1) to either 24 or 48 weeks of peginterferon-alpha-2a (180 microg/week) and ribavirin (1000-1200 mg/day) with a 24-week follow-up.” PMID 18508296 ↗ Jun 2008 “Pilot Study on Efficacy and Tolerance of Peg-interferon Alpha-2a (Pegasys) Added to Tenofovir DF and Emtricitabine (Truvada) in AGHBe Positive HBV-HIV Co-infected Patients.” NCT00391638 ↗ “Peginterferon alpha-2a (40KD) is a modified form of interferon alpha-2a consisting of a branched polyethylene glycol (PEG) chain covalently bound to interferon alpha-2a.” NCT00172809 ↗ “Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin” NCT00028093 ↗ “Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.” NCT06471673 ↗ “Induction Doses of Peginterferon Alpha-2a (40 KD) (270 μg/Week)” NCT00356486 ↗ |
| Known as | Peginterferon alpha-2a (40 kD) PEGASYS | “Peginterferon alpha-2a (40 kD) PEGASYS” NCT01380938 ↗ |
| Known as | peginterferon-alfa | “with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and” PMID 26248087 ↗ Aug 2015 |
| Known as | peginterferonα2a | “We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon α-2a (peginterferon) for a finite duration in a randomized trial.” PMID 26453773 ↗ Oct 20151“Treatment naïve patients with CHC, GT 2/3 were randomized to receive 180 μg peginterferonα2a/week in combination with either 800 (group C) or 400 mg/d (group D) for 16 weeks.” PMID 21714878 ↗ Jun 2011 |
| Known as | Pegnano (Peginterferon alfa-2a) | “Pegnano (Peginterferon alfa-2a)” NCT06922643 ↗ |
| Known as | pegylated interferon | “Less than half of patients infected with hepatitis C virus (HCV) achieve sustained viral clearance after pegylated interferon (peginterferon) and ribavirin therapy.” PMID 20854821 ↗ Sep 20101“The sustained-release form of the drug, pegylated interferon, is given just once a week.” NCT00023322 ↗ |
| Known as | Pegylated Interferon (Peginterferon) Alfa-2a | “Pegylated Interferon (Peginterferon) Alfa-2a” NCT01706575 ↗ |
| Known as | pegylated interferon alfa-2a | “A Phase II Randomized, Multicenter, Open-label Study of TG4040 (MVA-HCV) in Combination With Pegylated Interferon Alfa-2a and Ribavirin Versus Pegylated Interferon Alfa-2a and...” NCT01055821 ↗79“The aim of this study was to compare the pharmacokinetic properties of BIP48 (pegylated interferon alfa-2b from Bio-Manguinhos/Fiocruz, Brazil) to those of PEGASYS®...” PMID 29301580 ↗ Jan 2018 “An Open-Label Safety and Tolerability Study of Nitazoxanide, Pegylated-Interferon Alfa 2a and Ribavirin in HIV/HCV Co-Infected Genotype 1 Prior Treatment Relapsers and Non-Responders” NCT01185028 ↗ “pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment” NCT00085917 ↗ “Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.” PMID 25152207 ↗ Aug 2014 “Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.” NCT00132210 ↗ “A Phase II Study of Adefovir Dipivoxil, Pegylated Interferon Alfa-2A, and Ribavirin Treatment in HBV and HCV Infected Subjects With HIV Disease” NCT00051077 ↗ “Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.” PMID 18650451 ↗ Jul 2008 “Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week” NCT02021643 ↗ “Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks” NCT00629967 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.” NCT01188772 ↗ |
| Known as | pegylated interferon Alfa-2a (40KD) | “A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.” PMID 25190434 ↗ Sep 2014 |
| Known as | Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) | “Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche)” NCT00491244 ↗ |
| Known as | Pegylated interferon alfa-2a (Pegasys, Hoffman-La Roche) | “Pegylated interferon alfa-2a (Pegasys, Hoffman-La Roche)” NCT00917358 ↗ |
| Known as | pegylated interferon-alpha | “pegylated interferon-alpha (Pegasys)” NCT00909129 ↗ |
| Known as | pegylated interferon-α2a | “A Multicenter, Single-arm Trial Evaluating the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-IFNα2a/RBV) in Protease...” NCT01500772 ↗1“pegylated interferon-α2a, 135 µg weekly, plus” PMID 24297189 ↗ Dec 2013 |
| Known as | pegylated-interferon alpha-2a | “After medical evaluation and pretreatment liver biopsy, treatment with subcutaneous injections of pegylated interferon alpha-2a 180 g per week will be given for a total of 24...” NCT02364336 ↗35“pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1...” NCT00629824 ↗ “Coinfected and monoinfected patients were enrolled in a treatment trial for pegylated-interferon alpha-2a (peg-IFN) + ribavirin.” PMID 17058240 ↗ Nov 2006 “pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks” NCT00629967 ↗ “Pegylated interferon-alpha 2a 180 micrograms s.c. weekly” NCT00909129 ↗ “nilotinib + pegylated interferon alpha 2a (PEG-IFN).” NCT01294618 ↗ |
| Known as | pIFN | “pIFN (peginterferon alfa-2a)” NCT07288112 ↗ |
| Known as | Ro25-8310 | “A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon Alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control” NCT01519960 ↗1“A Phase III Study of Ro25-8310 (Peginterferon Alfa-2a) in Combination With Ro20-9963 (Ribavirin) in Patients With Chronic Hepatitis C” NCT00144469 ↗ |
| Action | Inhibit | “will suppress Hepatitis C virus” NCT00006164 ↗ |
| Modality | Protein / enzyme biologic | “Peginterferon alfa-2a (pegylated interferon)” NCT00006164 ↗ |
| Route | Other | “90 mcg/week injection” NCT00006164 ↗ |